<DOC>
	<DOC>NCT02477826</DOC>
	<brief_summary>The purpose of this study is to show that nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in subjects advanced lung cancer</brief_summary>
	<brief_title>A Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects with histologically confirmed Stage IV or recurrent NSCLC squamous or nonsquamous histology, with no prior systemic anticancer therapy Subjects must have programmed deathligand 1 (PD L1) immunohistochemical (IHC) testing, with results, performed by the central lab during the Screening period Eastern Cooperative Oncology Group (ECOG) Performance Status of â‰¤ 1 Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria Subjects with untreated Central nervous system (CNS) metastases are excluded Subjects with an active, known or suspected autoimmune disease are excluded Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>